Related Experiment Video
Updated: Jun 6, 2025
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Testing Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy
Yasmin Shakiba1, Masmudur M Rahman2,3
1School of Medical and Biological Physics, Moscow Institute of Physics and Technology, Moscow, Russia.
Abstract:
Oncolytic viruses (OVs) have emerged as a class of novel cancer immunotherapeutic. Members of both DNA and RNA viruses developed as OVs for treating diverse types of human cancers. Preclinical research assessing immunotherapeutic efficacy is an essential step toward further development of these OVs. Mice tumor model systems are widely used in preclinical oncolytic viral therapies for evaluating the treatment regimens' efficacy. However, choosing the most appropriate model for a study can be challenging. Here, we describe a simple method of establishing subcutaneous tumors in immunocompetent mice, intratumoral injection of the virus, measuring tumor burden, and studying the survival of mice for preclinical development of oncolytic myxoma virus (MYXV).
Insights
This study presents a straightforward method for evaluating oncolytic viruses (OVs) in preclinical cancer research. The described mouse tumor model facilitates the assessment of OV efficacy and survival outcomes for cancer immunotherapy development.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Oncolytic viruses (OVs) are emerging as a promising cancer immunotherapeutic strategy.
- Both DNA and RNA viruses are being developed as OVs to treat various human cancers.
- Preclinical research is crucial for advancing OV development, with mouse tumor models being widely utilized.
Purpose of the Study:
- To describe a simple and effective method for establishing subcutaneous tumors in immunocompetent mice.
- To detail the process of intratumoral virus injection, tumor burden measurement, and survival analysis for preclinical OV studies.
- To facilitate the preclinical development of oncolytic myxoma virus (MYXV).
Main Methods:
- Establishment of subcutaneous tumors in immunocompetent mice.
- Intratumoral administration of oncolytic viruses.
- Monitoring of tumor burden and mouse survival.
- Utilizing a mouse tumor model system for evaluating treatment efficacy.
Main Results:
- A reproducible method for generating subcutaneous tumors in mice was established.
- The protocol allows for effective intratumoral delivery and assessment of OV efficacy.
- Tumor burden and survival data were collected to evaluate the therapeutic potential of OVs.
Conclusions:
- The described method provides a simple yet robust approach for preclinical oncolytic virus therapy research.
- This model system is suitable for evaluating the efficacy and survival impact of oncolytic viruses, including MYXV.
- The findings support the continued development of oncolytic viruses as a cancer immunotherapeutic modality.
